Johnson & Johnson

Johnson & Johnson carries an Alpha Score of 62.2, with momentum at 78.5 and quality at 75.2 pulling the composite higher. Value scores a weak 39.2, reflecting a P/E of 30.72 — well above the sector median. EPS growth of 320.3% year-over-year is dramatic but likely distorted by a low prior-year base; the 8.1% revenue growth is more representative of underlying trends. Net margin of 21.5% supports the quality score. The stock sits near the upper half of its 52-week range ($164.74-$267.24). Next quarter's earnings will test whether the momentum can hold against the valuation premium.

Johnson & Johnson sits at a 44 Alpha Score, dragged by a 64.5 momentum reading that suggests the stock has been moving with the broader healthcare sector. Sentiment sits at 50, neutral. The missing pieces are value and quality — both null. That means the market hasn't yet priced in a clear earnings or margin story, and the company's defensive reputation alone isn't driving conviction. Forward watch: the next catalyst is the quarterly earnings report in mid-July. If JNJ shows revenue growth from its medtech division or a clearer path for the consumer health spin-off, the quality and value scores could harden. Until then, momentum without fundamental support is a fragile anchor.

Johnson & Johnson slipped 0.3% Monday, tracking a broader healthcare sector that gave back some of last week's gains. The stock sits near the middle of its 52-week range, with the Alpha Score at 42.9 held up almost entirely by momentum — that sub-score sits at 61.9, suggesting the recent uptrend still has some technical support. Sentiment is neutral at 50, which means options flow and short interest aren't flashing any strong signals either way. The value and quality sub-scores are null, so the model isn't finding a fundamental edge here on earnings or balance sheet metrics. JNJ's next catalyst is the July 17 earnings report. The market will be watching whether the consumer health spin-off's margin trajectory holds, and whether the talc litigation overhang has any new developments. Until then, the stock looks range-bound.

Johnson & Johnson shares sit near the middle of their 52-week band, with the talc litigation story back in focus. The company offered $5.5 billion to resolve roughly 76,000 lawsuits, a deal that needs 95% plaintiff approval. If it clears, the legal cloud that has dogged the stock for years lifts. If it doesn't, the uncertainty drags on. The numbers tell a mixed story. Revenue grew 8.1% year over year, but EPS dropped 7.8%. Net margin sits at a healthy 21.5%. The Alpha Score of 59.6 is dragged down by value (39.4) and sentiment (50), while momentum scores 82.9. That momentum reflects the stock's recovery from its 52-week low of $164.23, but the P/E of 30.14 leaves little room for error. The settlement vote is the next real catalyst. Watch for the approval tally in coming weeks.

Johnson & Johnson shares are getting a fresh catalyst after the FDA cleared its Ottava surgical robot for use. The De Novo authorization opens a $6 billion market that Intuitive Surgical has dominated for years. J&J now has a direct competitor in robotic-assisted surgery, a segment where it has tried and failed before. The stock sits near the middle of its 52-week range, with a P/E just under 30. Momentum is the strongest piece of the Alpha Score at 82.3, while value lags at 40.2. Quality scores a solid 75.5, reflecting net margins above 21%. Revenue grew 8.1% last year, and EPS jumped 320% — though that number is skewed by a low base. The Ottava approval gives the healthcare giant a new growth leg at a time when its pharmaceutical pipeline faces patent cliffs. The next question is how fast hospitals adopt the system against Intuitive's installed base. J&J reports next quarter in mid-April.